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Table 1:  Categories of evidence for management strategies in asth-
ma (Reproduced with permission from Global Initiatives for 
Asthma 2006) 
Evidence Category Sources of Evidence 
A Randomised controlled trials. Rich body of data. 
B Randomised controlled trials. Limited body of data. 
C Nonrandomised trials. Observational studies. 
D Panel consensus judgment. 
Introduction
Asthma prevalence is increasing worldwide and sur-
veys indicate that the majority of patients in developed 
and developing countries do not receive optimal care 
and are therefore not well controlled. The aim of these 
guidelines is to promote a better standard of treatment 
based on advances in the understanding of the patho-
physiology and pharmacotherapy of asthma and to en-
courage uniformity in the management of asthma. 
The South African Thoracic Society first published 
guidelines for the management of chronic persistent 
asthma in 1992 and the second revision in 2000. The 
current revision is prompted by: 
• The revised classification and new evidence on the 
safety and optimal use of asthma medication 
• An ongoing need to emphasize the use of anti-inflam-
matory medication as the foundation of asthma treat-
ment 
• The positioning of leukotriene modifiers in the mainte-
nance treatment of chronic asthma 
• An emphasis on defining and achieving control of 
asthma 
ESSENTIAL STEPS IN THE MANAGEMENT OF 
ASTHMA TO ACHIEVE CONTROL:
A. Establish the diagnosis of asthma............20 
B. Assess severity...........................................21 
C. Implement asthma treatment ....................21
1. Set goals for control of asthma 
2. Preventive/avoidance measures 
3. Pharmacotherapy 
D. Achieve and monitor control .....................25
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EVIDENCE
The strategies recommended in these guidelines are 
classified according to the Evidence Category in 
Table 1 and denoted as “Evidence A, B, C and D.
For details about these see Table 10 in the Additional 
Notes section.
This 2007 asthma guideline update was developed follow-
ing a meeting with a working group constituted by the SA 
Thoracic Society. The working group is chaired by Prof UG 
Lalloo. The contribution by the working group is gratefully 
acknowledged. 
Meetings were held with the working group on the 2  3 July 
2005, subsequently the editorial board was convened and 
met on the 30 March 2007 to develop and finalize this guide-
line document.  The meetings were sponsored by the Na-
tional Asthma Education Program (NAEP) of the SA Thoracic 
Society. This was possible through unrestricted educational 
grants to NAEP from the SA Thoracic Society, GSK, Astra-
Zeneca, MSD, Altana Madaus and Boeringher Ingelheim. 
The document is viewed as a living document that will be 
updated periodically. 
© SA Thoracic Society. All intellectual rights to the document belong to the SA Thoracic Society. 
No organisation or individual has been assigned exclusive publication rights to this document.
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A. ESTABLISH THE DIAGNOSIS OF ASTHMA 
1. Definition of asthma 
Asthma is a chronic inflammatory condition of the airways 
which is usually allergic in origin and is characterised by 
hyperresponsive airways that constrict easily in response 
to a wide range of stimuli. 
2. Symptoms and signs of asthma 
The characteristic symptoms of asthma are cough, 
wheeze, dyspnoea or shortness of breath, and tightness 
of the chest. 
Patterns of symptoms that suggest asthma are: 
• Variability: day and night, day to day, seasonal 
• Precipitation by a range of factors including environ-
mental allergens (house dust mite, grass pollens, animal 
dander, occupational exposures), non-specific irritants 
(smoke, dusts and fumes), cold weather and exercise
• Response to bronchodilators and corticosteroids 
Wheeze is a cardinal sign of asthma but may be absent at 
the time of consultation because airway constriction does 
not always result in detectable signs. 
3. Lung function in asthma 
Spirometric lung function tests, including measurement of 
peak expiratory flow, are useful in the diagnosis, assess-
ment of severity and management (monitoring) of asthma. 
It may be abnormal even when symptoms and signs are 
absent. It may also be normal when asthma is quiescent. 
The commonest abnormality is a reduction in forced ex-
piratory volume in 1 sec (FEV1) and peak expiratory flow 
(PEF). The ratio of FEV1 to forced vital capacity (FVC) to 
below 70% is characteristic of obstructive airways disease. 
The degree of reduction is generally related to severity of 
the asthma. Asthma improvement is usually mirrored by an 
improvement in FEV1 and PEF. 
Significant reversibility of the airway obstruction is the 
major physiological characteristic of asthma. The stan-
dardised criteria are an increase in FEV1 of >12% and 
200 ml, 15-30 min following the inhalation of 200-400 µg of 
salbutamol, or a 20% improvement in PEF from baseline. 
It should be noted, however, that many asthma patients 
will not exhibit reversibility at each assessment, particularly 
those on treatment, and thus the test lacks sensitivity and 
repeated testing at different visits is advised. 
Conversely, asthma can also be confirmed by demonstrat-
ing increased hyperresponsiveness to bronchoconstrictor 
stimuli, particularly in subjects with normal spirometry. This 
is the principle of the methacholine/histamine challenge 
test. Exercise-induced bronchoconstriction may also be 
used to diagnose inducible airway obstruction. The FEV1
or PEF is measured at baseline and the patient asked to 
exercise (e.g. run for about 6 min) and the measurements 
repeated 5-10 minutes following cessation of exercise. A 
fall of 20% in PEF (15% in FEV1) in this setting is supportive 
of a diagnosis of asthma. Exercise induced bronchocon-
striction may be the only manifestation of asthma in some. 
Another option is to demonstrate diurnal variation in 
PEF of more than 20%. This can also be used to identify 
environmental (including occupational) causes of asthma 
symptoms by monitoring PEF 2-4 times each day for at 
least 2 weeks. To measure diurnal variation, the PEF is 
measured first thing in the morning before treatment is 
taken, when values are often lowest, and last thing at night, 
when values are usually higher. There are several methods 
of calculating the diurnal PEF variability. A common way 
is the difference between the maximum and the minimum 
value for the day, expressed as a percentage of the mean 
daily PEF value, and averaged over 2 weeks. 
If spirometry shows obstruction, a 2 week trial of oral pred-
nisone (40 mg daily) may help to distinguish asthma from 
chronic obstructive pulmonary disease (COPD). In asthma 
there would be a significant improvement in FEV1  from 
baseline (>12% and 200 ml).
4. Making/confirming the diagnosis of asthma 
The diagnosis of asthma is made by following these 
steps: 
Step 1
Suspect asthma on basis of symptoms and signs particularly if 
there is variability
The optional tests are generally more costly but may be re-
quired as supportive evidence for asthma when the clinical 
and lung function data is not confirmatory. Measurement 
of exhaled nitric oxide (NO) and allergen challenge tests 
should only be done in research centres. 
Step 2
Search for associated factors such as: 
a. Related atopic disorders – allergic rhinitis, allergic 
conjunctivitis, eczema 
b. Family history of asthma or other allergic disorders 
c. Onset of, or presence of symptoms during childhood 
d. Identifiable triggers for symptoms, and relieving 
factors such as improvement with a bronchodilator, or 
deterioration with exercise 
e. Exposure to known asthma sensitizers in the 
workplace (Table 8 in Additional Notes). 
f. Conduct spirometric lung function test or measure 
PEF. Repeat 15-30min after administration of 200-
400µg of salbutamol, preferably via a spacer to 
ensure drug delivery to the airways. 
g. Optional tests include: 
• Full blood count to check eosinophil count 
• Total serum IgE 
• Skin prick tests or RAST in blood to look for 
evidence of atopy 
• Methacholine or histamine or exercise 
challenge tests
Diagnostic lung function values
Reversibility:
•  An increase in FEV1 of >12% and 200 ml, 15-30 min after the  
    inhalation of 200-400ìg of salbutamol, or a 20% improvement  
    in PEF from baseline. 
Hyperresponsiveness:
•  Methacholine/histamine challenge
•  Exercise: A fall of 20% in PEF (or 15% in FEV1) measured  5-10 
    minutes apart after cessation of exercise (e.g. running for 6 
    minutes)
Diurnal variation:
•  Diurnal variation in PEF of more than 20%
Distinguishing between COPD and asthma when FEV1 shows 
obstruction:
•  Improvement of FEV1 from baseline (>12% and 200ml) after a 2  
    week trial of oral prednisone (40 mg daily).
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CONTROLLERS RELIEVERS 
Anti-inflammatory action to prevent 
asthma attacks
Sustained bronchodilator action but weak 
or unproven anti-inflammatory effect
For quick relief of symptoms and use in 


























B. ASSESSMENT OF ASTHMA SEVERITY 
When asthma is first diagnosed, it is convenient for imple-
mentation of treatment to classify it as mild intermittent
or chronic persistent asthma that is mild, moderate or 
severe (Table 2). However, the severity is variable, does 
not predict response to treatment and is of little value in pa-
tients already on treatment. Periodic assessment of asthma 
control and review of management are more relevant.
Table 2:  Assessment of asthma severity using symptoms and PEF in 
patients presenting for the first time on no treatment 
INTERMITTENT CHRONIC PERSISTENT 
Mild Mild Moderate Severe 

































*any of cough, tight chest and wheeze; 
** any of cough, tight chest, wheeze and night wakening
C. IMPLEMENT ASTHMA TREATMENT 
1.  SET GOALS OF ASTHMA TREATMENT TO ACHIEVE 
CONTROL 
The emphasis of modern asthma treatment is to achieve 
control. A patient’s asthma is well controlled when the 
goals of asthma management are achieved and main-
tained. The Global Initiative for Asthma (GINA) goals for 
asthma treatment is widely acknowledged and are: 
a. Achieve and maintain control of symptoms 
b. Maintain normal activity levels, including exercise 
c.  Maintain pulmonary function as close to normal as possible
d. Prevent asthma exacerbations 
e. Avoid adverse effects from asthma medications 
f. Prevent asthma mortality. 
Achievement of the goals will also reduce asthma-related 
morbidity and mortality. 
2. PREVENTATIVE/AVOIDANCE MEASURES 
Avoidance of triggers wherever possible helps to minimise 
asthma severity and reduces asthma exacerbations. Prac-
tical measures include: 
a.  Avoid exposure to personal and second-hand tobacco 
smoke 
b. Avoid contact with furry animals 
c. Reduce pollen exposure 
d. Reduce exposure to house dust mite 
e.  Avoid sensitisers and irritants (dust and fumes) which 
aggravate or cause asthma especially in the workplace 
f. Avoid food and beverages containing preservatives 
g.  Avoid drugs that aggravate asthma such as beta block-
ers (including in eye drops), and aspirin and non-steroi-
dal anti-inflammatory drugs 
3. PHARMACOTHERAPY 
Maintenance treatment of asthma is determined by sever-
ity on presentation, current asthma medication, patient 
profile and level of control. 
A classification of asthma drugs based on current knowl-
edge of their mode of action is presented in Table 3. They 
may be: 
• Relievers  short-acting bronchodilators with rapid onset 
of action that provide acute relief of symptoms 
• Controllers  drugs with anti-inflammatory and/or a sus-
tained bronchodilator action 
Prescribers should be acquainted with the trade names, 
formulations, dosage and mode of administration of each 
preparation. The inhaled route is recommended as drugs 
are delivered directly into the airways with higher lung 
concentrations and less systemic side effects. Inhaled 
medications for asthma are available as pressurised me-
tered-dose inhalers (pMDIs), breath-actuated MDIs, dry 
powder inhalers (DPIs), soft mist inhalers and nebulisers. 
It requires training and skill to coordinate activation of the 
pMDI with inhalation. All patients using a pMDI should use 
a large volume (500 ml) spacer or holding chamber to im-
Table 3: Classification of drugs used in the maintenance treatment of asthma 
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STEROID PREPARATION 
EQUIVALENT METERED DOSE IN 
ASTHMA 
Beclomethasone dipropionate 250 µg 
Budesonide 200 µg 
Fluticasone propionate 100 µg 
Ciclesonide 80 µg 
prove drug delivery to the lungs and reduce local and sys-
temic side effects. A pMDI plus spacer is as effective as 
a DPI (Evidence A). An inhaler device should be chosen 
and prescribed after patients have received training in its 
use and have shown satisfactory technique (Evidence B).
See section C for Additional Notes on inhaler devices. 
Treatment combinations are necessary in patients with 
more severe asthma or mild asthma not responsive to low 
dose inhaled corticosteroids. 
CONTROLLERS 
There are 2 groups of controllers  those with anti-inflam-
matory action (corticosteroids and leukotriene blockers) 
and those with a sustained bronchodilator action (long-
acting ß2 agonists and slow-release theophyllines). 
Anti-inflammatory agents 
Anti-inflammatory treatment is recommended for all 
patients with chronic persistent asthma. Inhaled cortico-
steroids are the most widely studied and recommended 
drugs in this class. Leukotriene modifiers are effective but 
less so than inhaled corticosteroids. 
Corticosteroids 
Inhaled corticosteroids are the mainstay of treatment for 
patients with chronic persistent asthma (Evidence A).
The inhaled route is preferred because delivery direct to 
the lungs permits the use of lower doses. The equivalent 
effective doses of currently available inhaled corticoste-
roid preparations for prescription in asthma are com-
pared to 200 µg beclomethasone dipropionate in Table 
4. Through its anti-inflammatory effects, inhaled cortico-
steroids reduce airway inflammation, decrease bronchial 
hyperresponsiveness and improve asthma control. In ad-
dition, they may modify airway remodelling and prevent 
an accelerated decline in lung function. Their long-term 
use in adequate doses has been shown to decrease ex-
acerbations and mortality. 
Systemic absorption of inhaled corticosteroids arises 
from oropharyngeal absorption and to a lesser extent 
from drug deposited in the lungs. This may be reduced 
by the use of a spacer device combined with mouth 
washing after inhalation (Evidence A). The former in-
creases the fraction delivered to the lung (Evidence A).
Both measures reduce the incidence of local side effects 
such as dysphonia and oropharyngeal candidiasis. 
Inhaled corticosteroids are generally administered twice 
daily and may be used once daily as well. A low starting 
dose is 200-500 µg/day of BDP equivalent and a dose 
above 1000 µg /day is considered a high dose. At higher 
doses, the dose-response curve is relatively flat but the 
risk of systemic side effects such as skin bruising, cata-
racts and osteoporosis may be increased. Patients re-
quiring long term use of high dose inhaled corticosteroids 
should be referred to a specialist for review. Strategies to 
minimise osteoporosis such as regular exercise, calcium 
supplementation and hormonal replacement in post-
menopausal women should be considered. 
A preferred strategy to minimise the dose of corticoste-
roids and improve control is the combination of long-act-
ing ß2 agonists (salmeterol or formoterol) with lower doses 
of inhaled corticosteroids (Evidence A). An alternative 
is the combination of lower dose inhaled corticosteroids 
with leukotriene modifiers (Evidence A). If these are un-
available, combination with slow-release theophyllines 
are a weaker alternative (Evidence B). Long-acting ß2
agonists, leukotriene modifiers and slow-release theoph-
ylline must always be used in combination with at least 
low dose corticosteroids for maintenance treatment of 
asthma. 
Nebulised corticosteroids are expensive, require high 
pressure nebulisers for optimal delivery and are not 
recommended for routine use in acute and chronic 
asthma. 
Oral corticosteroids may be considered in patients 
with poorly controlled asthma on high doses of inhaled 
corticosteroids and other controller medications. Long 
term oral corticosteroids (>7.5mg prednisone/day), 
whilst relatively inexpensive, are associated with serious 
systemic side-effects. Such patients should be referred to 
a specialist for review. Alternate day dosing may reduce 
side effects (Evidence D).
Leukotriene modifiers 
Leukotriene modifiers have been shown to improve 
asthma control and exert their effect within days of 
commencing treatment. They may be used in patients 
with at least mild persistent asthma as add-on treatment 
to inhaled corticosteroids (Evidence A) and may be 
of value in patients with aspirin-sensitive asthma. If no 
benefit is evident after 4 weeks, the leukotriene modifiers 
should be withdrawn since not all patients respond. Their 
routine use as monotherapy in asthma in adults is not 
advised (Evidence D).
Sustained action bronchodilators 
Long-acting ß2 agonists (LABAs) 
Salmeterol and formoterol are LABAs administered twice 
daily because of their greater than 12 hour duration 
of action. They are useful for control of nocturnal 
symptoms and exercise-induced asthma. They are 
recommended as an addition to low dose inhaled 
corticosteroids in preference to increasing the dose of 
inhaled corticosteroids (Evidence A). Salmeterol is not 
suitable for acute relief of asthma symptoms because 
it has a delayed onset of action and is limited by the 
ceiling dose of 50 µg BD. Formoterol has a rapid onset 
Table 4: Equivalent effective metered doses of inhaled corticosteroids 
CPD: National Guidelines
SA Fam Pract 2007:49(5)24
CHARACTERISTIC CONTROLLED (All of the following) 
PARTLY CONTROLLED 
(Any measure present in 
any week) 
UNCONTROLLED 
Daytime symptoms <2/week >2/week
3 or more features of partly controlled 
asthma in any week 
Limitation of activities None Any
Nocturnal symptoms/
awakening None Any
Need for reliever/ rescue 
treatment <2/week) >2/week
Lung function (PEF/FEV1) Normal
<80% predicted or personal 
best (if known)
Exacerbations None 1or more/year* 1 in any week** 
Table 5: Levels of Asthma Control 
* Any exacerbation should prompt review of maintenance treatment to ensure that it is adequate. 
** By defi nition, an exacerbation in any week makes that an uncontrolled asthma week. 
of bronchodilation (within 10-15mins of administration) 
and has a wide dose range. LABAs should never be used 
without inhaled corticosteroids in asthma because current 
evidence suggests an increased risk of deaths if LABAs 
are used as monotherapy. Some patients may not respond 
to LABAs. Side effects of these drugs include palpitations 
and tremor. 
Slow-release (SR) theophyllines 
Most formulations of SR theophyllines have a 12 hour and 
some a 24 hour duration of action. They are administered 
orally and have a complementary mode of action to 
other bronchodilators. Their disadvantages include a 
narrow therapeutic range, drug interactions and frequent 
side effects (nausea, vomiting, abdominal pain, gastro-
oesophageal reflux, palpitations, insomnia, irritability and 
seizures). They should not be used as monotherapy. There 
is no role for oral short-acting theophyllines in chronic 
asthma. 
RELIEVERS 
These include short-acting inhaled ß2  agonists (SABAs) 
and the anti-cholinergic ipratropium bromide. They should 
be used on an as needed basis as rescue medication. 
Short-acting ß2 agonists (SABAs) 
Short-acting ß2 agonists (e.g. salbutamol and fenoterol) 
provide relief from acute symptoms of asthma and are 
usually used as 2 puffs as needed (Evidence A). With 
optimal maintenance therapy their use should be rare (less 
than once a day). The frequency of their use is a measure 
of asthma control. They are the most important and widely 
used reliever treatment for asthma. 
They may only be used as the sole therapy in mild 
intermittent asthma where the symptoms are mild and 
infrequent (<2x/week) and the lung function is normal (PEF 
> 80% predicted), see Table 2. In chronic persistent asthma 
they should only be used on an as needed basis as rescue 
medication. Some patients with severe persistent asthma 
may need to use short-acting ß2 agonists up to 6 times 
per day. Side effects of ß2 agonists include tachycardia, 
tremor, headache and irritability. 
Anti-cholinergics (ipratropium bromide)  
This drug works by inhibiting vagally-mediated broncho-
constriction and is not the preferred reliever in asthma. It 
may be used in patients, particularly the elderly, who can-
not tolerate ß2 agonist side effects. It may also be of val-
ue as add-on treatment in patients who do not obtain ad-
equate symptom relief with the short-acting ß2 agonists 
alone (Evidence B). 
ADDITIONAL TREATMENT AND OTHER DRUGS 
• Antihistamines are not effective in adult asthma. 
•  Immunosuppressives including methotrexate are rarely 
of benefit. Patients considered for this treatment must 
be referred to a specialist. 
•  There is little scientific evidence that ionisers, oxygen 
therapy, acupuncture, homeopathy and exclusion diets 
are useful in the treatment of asthma. Their prescription 
is not recommended in this guideline. 
•  Desensitisation using immunotherapy (including 
sublingual) is not routinely recommended for asthma. 
Patients with refractory asthma sensitised to only one 
allergen such as house dust mite or grass pollen may 
be referred to a specialist for immunotherapy. 
•  Nebuliser use in chronic persistent asthma must be 
actively discouraged. With good inhaler technique 
assisted by spacer devices, adequate drug delivery 
via an inhaler is achieved with similar bronchodilatation 
even in patients with chronic severe asthma and 
inability to generate large airflow rates. Nebulisers are 
not a substitute for adequate controller treatment. 
TREATMENT OPTIONS 
All patients should be prescribed inhaled short-acting ß2
agonists such as salbutamol; 200 µg (2 puffs) as needed 
for use as symptom relief for acute asthma symptoms 
(Evidence A). All patients should receive inhaled 
corticosteroids as baseline asthma treatment except 
those classified as mild intermittent asthma according to 
the criteria in Table 2 (Evidence A). 
CPD: National Guidelines
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The dose of corticosteroids and additional treatment is 
determined by: 
1. The severity of asthma 
2. The response to treatment 
The recommended treatment plan is: 
to PEF and symptom frequency. 
Treatment with short courses of oral prednisone should 
be considered in known or newly diagnosed asthmatics 
in the following circumstances in order to prevent severe 
deterioration and to gain rapid control of asthma: 
•  Symptoms and/or lung function (PEF) progressively 
deteriorating acutely or over several days and associated 
with increased use of inhaled rescue medication 
• Lack of sustained relief from rescue medication 
•  Repeated drops in PEF over 1 or more days to below 
60% of previous best value 
• Frequent night time symptoms 
• Requirement for emergency treatment 
Recommended procedure for the prescription of a short 
course of oral prednisone 
• Prednisone 30-40mg / day for 7-14 days 
• Once daily (morning) dosing 
•  Stop abruptly after course (there is no need to tail off if 
used for the recommended duration) 
•  Inhaled corticosteroids for maintenance treatment 
should be commenced or continued 
•  A step-up in maintenance controller treatment is usually 
indicated 
•  Patients requiring oral corticosteroids for more than 14 
days should be referred to a specialist.  
ASTHMA EDUCATION 
Optimal management of a chronic disease like asthma 
requires the active participation of patients. To achieve 
this patients require education about asthma and a 
detailed written management or action plan (Evidence A).
A systematic approach is necessary to ensure that all 
relevant details are included and education should be 
staged over several visits. Details of a self management 
plan are presented in Section F of Additional Notes. 
The use of nurse educators and other specially trained 
healthcare professionals is cost-effective. Goals of asthma 
education include: 
•  An explanation of the nature of asthma and its allergic 
basis 
•  A description of the different classes of drugs and their 
purpose in treatment (i.e. as-needed “relievers” and 
regular “controllers”) 
•  Advice on prevention strategies (allergen and tobacco 
smoke avoidance) 
•  The correct choice and use of inhalers and the 
opportunity to practice under supervision 
• How to recognise worsening asthma 
•  In some patients, particularly those requiring stabilisation 
or patients who have had a recent exacerbation or 
deterioration, the use of a PEF meter and chart 
•  Introduction to the National Asthma Education 
Programme (NAEP)  the official asthma education 
programme of the South African Thoracic Society. This 
provides educational material for the self management 
of asthma. Contact details are provided in Section G of 
Additional Notes. 
Figure 1 is a summary of the treatment plan. 
D. ACHIEVE AND MONITOR CONTROL 
Patients should be reviewed frequently until control is 
achieved and thereafter less often. A self management 
plan is recommended for all patients (see Section F of 
Additional Notes). Asthma control may be assessed using 
a simplified scheme for recognising controlled, partly 
controlled, and uncontrolled asthma in a given week as 
provided in Table 5 (Evidence D). An exacerbation is 
defined as an increase in asthma symptoms requiring a 
consultation with a health care provider. At each visit the 
patient should be assessed for adherence and level of 
asthma control. It is possible to achieve complete control 
of asthma in most patients and this should be achieved 
with minimal side effects.. Validated measures for 
assessing clinical control of asthma are the Asthma Control 
Test (ACT) (http://www.asthmacontrol.com) or the Asthma 
Control Questionnaire (ACQ) (http://www.qoltech.co.uk/
Asthma1.htm). They are suitable for self-assessments by 
patients, and provide a reproducible objective measure 
that may be charted over time. 
Patients with poor asthma control should be assessed for 
the following: 
•  Reasons for poor adherence and misunderstanding the 
difference between relievers and controllers 
• Poor inhaler technique 
• Exposure to trigger factors at home and work 
• Presence of gastro-oesophageal acid reflux disease 
• Rhinitis and sinusitis 
•  Use of medications that may aggravate asthma such 
as aspirin, non-steroidal anti-inflammatory drugs and ß 
blockers 
• Other medical conditions (e.g. cardiac disease) 
Step up treatment when control is not achieved after 
attention to the above factors. Step down is recommended 
when total control is achieved and maintained for at least 
3 months. Within a self management plan, well-motivated 
patients could also be advised to vary treatment according 
1.  Add a LABA if asthma is not well controlled on low 
dose ICS (Evidence A). This option is preferred to 
doubling the dose of ICS; however, not all patients 
respond to LABAs. Never use LABAs alone. 
2.  An alternative is to double the dose of ICS or add 
leukotriene modifiers (Evidence A) or slow-release 
theophyllines (Evidence B) 
3.  Oral corticosteroids should only be used as 
maintenance treatment with extreme caution. 
4.  Referral to a specialist is recommended when 
asthma is difficult to control (see Section E Additional 
Notes).
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Daytime symptoms > twice/week
Any limitation of activity
Any nocturnal
symptoms/awakening
Need for reliever medication
> twice/week
Lung function <80% predicted or
personal best
1 exacerbation per year
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controlled asthma in any week
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Figure 1: Algorithm for diagnosis and management of chronic asthma
CPD: National Guidelines
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ADDITIONAL NOTES 
A.  DIFFERENTIAL DIAGNOSIS OF ASTHMA, WHEEZE 
AND AIRWAY OBSTRUCTION 
There are many causes of airway obstruction that cause 
symptoms and signs that may mimic asthma. These are 
listed in Table 6. Asthma must be distinguished from COPD 
particularly when a patient develops airway obstruction 
for the first time in the 5th decade or later. The features 
that help to differentiate between asthma and COPD are 
summarised in the Table 7. The SA Thoracic Society has 
issued guidelines for the diagnosis and management of 
COPD in a separate guideline statement. 
Table 6: Causes of airway obstruction 
WIDESPREAD AIRWAY 
OBSTRUCTION 
May present with wheeze. 
•  Asthma 
•  COPD 
•  Bronchiolitis 
•  Pulmonary congestion   
    /oedema (left ven  
    tricular failure, mitral  
    valve stenosis) 
TRACHEAL OBSTRUCTION 
May present with stridor 
•  Extrinsic compression 
    (thyroid, lymph nodes) 
•  Lesions in the lumen or 
    wall (stenosis, stricture, 
    tumour) 
•  Cartilage (tracheoma
    lacia, relapsing poly
    chondritis) 
BRONCHIAL OBSTRUCTION 
May present with localised 
wheeze 
•  Extrinsic compression 
    (lymph nodes) 
•  Lesions arising from 
    the wall (tumour, ste
    nosis, endobronchial 
    TB, sarcoidosis) Luminal 
    lesion (foreign body) 
LARYNX 
May present with wheeze 
and/or stridor 
•  Vocal cord dysfunction 
•  Tumours 
B. DIFFERENTIATING ASTHMA FROM COPD 
Table 7:  Differentiating features between asthma and COPD 
Features suggesting 
asthma 
Features suggesting COPD 
Young age of onset Long history of smoking 
Presence of atopy 
and/or allergic rhinitis 
Usually non-atopic
Diurnal and/or day to 
day and seasonal vari-
ation in symptoms and 
lung function 
Insidious onset of symptoms and persis-
tent dyspnoea 
Slow progression of symptoms 
Often normal examina-
tion and normal/near 
normal spirometry 
while in a stable state 
Hyperinflation and abnormal spirometry 
while in a stable state, 
Progressive deterioration in lung func-
tion over time 
Marked improvement 
after bronchodilator 
and/or 2 week trial of 
systemic corticoste-
roids*. 
Poor response to bronchodilator and/or 
2 week trial of systemic corticosteroids 
C.  ROUTES OF ADMINSTRATION OF ASTHMA DRUGS 
    INHALED, ORAL or PARENTERAL 
Asthma treatment for adults can be administered in differ-
ent ways: inhaled, orally or parenterally (by subcutaneous, 
intramuscular, or intravenous injection). The major advan-
tage of inhaled therapy is that drugs are delivered directly 
into the airways, producing higher local concentrations 
with significantly less risk of systemic side effects. Inhaled 
medications for asthma are available as pressurised me-
tered-dose inhalers (pMDIs), breath-actuated MDIs, dry 
powder inhalers (DPIs), soft mist inhalers, and nebulisers 
(rarely indicated for the treatment of chronic asthma in 
adults). 
Inhaler devices differ in their efficiency of drug delivery 
to the lower respiratory tract, depending on the form of the 
device, formulation of medication, particle size, velocity of 
the aerosol cloud or plume (where applicable), and ease 
with which the device can be used by the majority of pa-
tients. It requires training and skill to coordinate activation 
of the pMDI with inhalation, and a breath-actuated MDI 
may be helpful for patients who have difficulty with this. 
Most patients make mistakes with a pMDI alone. They are 
less likely to do so if they also use a large volume (500 
ml) spacer or holding chamber to improve drug delivery, 
increase lung deposition, and reduce local and systemic 
side effects. The drug should be given by repeated single 
activations of the MDI into the spacer, each followed by 
inhalation (normal/tidal breathing is as effective as single 
deep breaths). There should be minimal delay between 
pMDI activation and inhalation. The spacer should be 
compatible with the pMDI being used. Spacers should be 
cleaned monthly (washed in detergent and allowed to air 
dry) and ideally should be replaced at least every year. 
Dry powder inhalers are generally easier to use, but they 
require a minimal inspiratory flow rate which may be difficult 
for some patients. A pMDI + spacer is as effective as a DPI 
(Evidence A). Some patients may prefer a DPI or prefer not 
to carry a large volume spacer. Choice of delivery device 
should be based on correct technique and patient prefer-
ence. The patient should have their inhaler technique as-
sessed, ideally by a specifically trained health care worker. 
An inhaler device should be prescribed after patients have 
received training in its use and have demonstrated satis-
factory technique (Evidence B). Their inhaler technique 
should be continually reassessed as part of a structured 
clinical review (see Section F Asthma Education). In mild 
and moderate exacerbations of asthma, a pMDI + spacer 
is at least as good as a nebuliser in adults and children 
from the age of two (Evidence A). DPIs are not currently 
recommended for acute asthma (Evidence D).
CFC inhaler devices are being phased out due to the 
impact of CFCs upon the atmospheric ozone layer, and 
are being replaced by HFA devices. For pMDIs contain-
ing bronchodilators, the switch from CFC to HFA inhalers 
does not result in a change in efficacy at the same nominal 
*>12% and 200ml improvement in FEV1 or 20% in PEF 
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dose. However, for some glucocorticosteroids, the HFA 
formulations provide an aerosol of smaller particle size that 
results in less oral deposition (with associated reduction in 
oral side effects), and correspondingly greater lung depo-
sition. A spacer is thus only necessary with HFA inhalers 
if coordination is poor. This may result in greater efficacy 
at equivalent ex-actuator doses, but also greater systemic 
exposure and risk of side effects. Information on various in-
haler devices available can be found on the GINA Website 
(http://www.ginasthma.org). 
D. SPECIAL CLINICAL CIRCUMSTANCES 
There are several clinical circumstances where special 
precautions and adjustments to asthma management and 
treatment may be required. These are summarised as fol-
lows: 
Pregnancy
Ideally pregnancy should be planned and optimal control 
achieved prior to conception. The effect of pregnancy is 
unpredictable: asthma control may remain the same, de-
teriorate or improve and may vary in different trimesters in 
successive pregnancies. Current evidence suggests that 
corticosteroids, ß2 agonists and theophyllines are safe in 
pregnancy. New drugs for which safety data in pregnancy 
are not available should be avoided. It is essential that 
asthma should be optimally controlled during pregnancy 
through the use of appropriate doses of inhaled corticoste-
roids, which have been shown to decrease exacerbations. 
Acute exacerbations should be managed very actively to 
prevent foetal damage. Poor control of asthma is much 
more dangerous to both the mother and foetus than any 
asthma drug. 
Menstruation
Pre-menstrual exacerbations of asthma are common. The 
mechanism is not well understood. When severe they may 
require an increase in the dose of inhaled corticosteroids 
or a low dose of oral prednisone for 2-3 days commencing 
1-2 days before menstruation. 
Exercise
Exercise-induced asthma (EIA) may occur as an isolated 
symptom but is usually an indication of sub-optimal asthma 
control. The preferred treatment is the use of short-acting 
inhaled ß2 agonists 15-20 mins before exercise. Long-act-
ing ß2 agonists, leukotriene modifiers and SR theophyllines 
may protect against EIA for several hours after dosing. 
Elderly patients
Asthma occurs in the elderly and is frequently overlooked 
or misdiagnosed. The elderly are more susceptible to ad-
verse effects of drugs. SR theophyllines should be used 
with care because of their narrow therapeutic range and 
side effects. The elderly are also especially prone to the 
side effects of corticosteroids such as osteoporosis, cata-
racts, glucose intolerance, hypertension and fluid reten-
tion. 
Nocturnal asthma
Occasionally nocturnal symptoms are the sole manifesta-
tion of asthma and may be associated with marked falls in 
the PEF (50% or more). However, nocturnal symptoms are 
usually an important indicator of poor control and may sig-
nal the onset of impending severe deterioration. Long-act-
ing ß2 agonists and SR theophylline provide an additional 
benefit to that of anti-inflammatory therapy in controlling 
nocturnal symptoms. Sometimes a short course of oral 
corticosteroids is indicated. 
Cardiac disease and hypertension
Fluid retention and hypokalaemia induced by corticoste-
roids and high doses of ß2 agonists may occasionally be 
a problem in asthma with associated cardiac disease. 
Pulmonary congestion may manifest with wheezing and 
may be misdiagnosed as asthma particularly in patients 
with mitral stenosis and in the elderly. ß blockers are con-
traindicated in asthma. 
Diabetes mellitus 
Particular caution is required when prescribing oral corti-
costeroids. Inhaled corticosteroids are safe and have no 
significant effect on glycaemic control. 
Pulmonary tuberculosis
In patients who have had tuberculosis or evidence of 
healed tuberculosis on chest radiographs, chemoprophy-
laxis with isoniazid is not recommended whilst on inhaled 
or short course of oral corticosteroids as the risk of reacti-
vation has not been shown to be increased. 
Gastro-oesophageal acid reflux
Acid reflux may aggravate asthma and should be con-
sidered in patients with difficult asthma and in those with 
symptoms of acid reflux. The acid reflux may be asymp-
tomatic. 
Rhinitis and sinusitis 
These may aggravate asthma and should be considered 
in patients with difficult asthma even in the absence of 
specific symptoms. 
E. OCCUPATIONAL ASTHMA 
This should be considered in every patient who develops 
asthma in adulthood. It requires systematic enquiry into 
all work exposures. 
It is important to familiarise oneself with the common 
agents and jobs/industries that are known to cause oc-
cupational asthma and some of the these are listed in 
Table 8
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F. WHEN TO REFER TO A SPECIALIST 
in the management of their asthma. The partnership is 
formed and strengthened as patients and their health care 
professionals discuss and agree on the goals of treatment, 
develop a personalised, written self management action 
plan including self-monitoring, and periodically review the 
patient’s treatment and level of asthma control. The ability 
or willingness of patients to take responsibility varies and 
thus the information and skills training required by each 
patient will differ. All require certain core information and 
skills, but most education must be personalised. Action 
plans are one of the most effective interventions available 
in asthma for both adults and children and can be issued 
by any health care worker and used in all health care en-
vironments (especially in secondary care with moderate to 
severe disease, and those who have had recent exacer-
bations (Evidence A). They may be based on symptoms 
and/or peak flows (depending on age and ability). The use 
of a personalised written asthma action plan does not im-
prove lung function but does result in fewer days lost from 
work and school, fewer emergency department visits and 
hospital admissions, fewer nocturnal symptoms, less use 
of rescue medication and better quality of life. 
A systematic approach is necessary to ensure that all 
relevant details are included and education should be 
staged over several visits. The use of nurse educators and 
other specially trained healthcare professionals is cost-ef-
fective. 
Goals of asthma education include: 
•  An explanation of the nature of asthma and its allergic 
basis 
•  A description of the different classes of drugs and their 
purpose in treatment ( i.e. as-needed “relievers” and 
regular “controllers”) 
•  Advice on preventative strategies (allergen and tobacco 
smoke avoidance) 
•  The correct choice and use of inhalers and the opportu-
nity to practice under supervision 
•  Emphasis on the importance of regular follow-up and 
when to request earlier review 
•  How to recognise worsening asthma
• How to recognise potential side-effects of drugs 
Key components of a self-management plan:
• The use of a PEF meter and chart, particularly in those requiring 
stabilisation or patients who have had a recent exacerbation or 
deterioration, 
• Realistic goals of treatment in terms of symptom relief and/or PEF 
• Advice on how to recognise changes in the asthma (via symptoms 
and/or peak flow rates) and when to make adjustments to treat-
ment according to a predetermined schedule 
• Written instructions on treatment which include the class, name, 
strength, dose and frequency of each of the asthma medications 
prescribed 
• Instruction on when and how to initiate short courses of oral predni-
sone
• Details on when and how to obtain access to medical care in 
emergencies
• Arrangements for a Medic-Alert for patients on high dose inhaled 
or oral corticosteroids, known drug hypersensitivities (like aspirin 
and penicillin) and brittle asthma 
A. DIFFICULTY WITH DIAGNOSIS
• Patients receiving multiple courses of antibiotics 
• Possibility of COPD 
• Asthma for the fi rst time after the age of 60 years 
• Suspected vocal cord dysfunction 
B. SUSPECTED OCCUPATIONAL ASTHMA 
C. MANAGEMENT PROBLEMS
• Brittle asthma 
• Recurrent exacerbations >2 per month 
• Recent discharge following admission for severe exacerbation
• Oral corticosteroid dependence 
• Poor control despite intensive treatment 
• Pregnancy 
• Co-existing signifi cant medical illnesses like thyroid disease, 
collagen vascular disease, peptic ulcer, cardiac failure 
• Frequent school or work absenteeism 
• Signifi cant corticosteroid side effects 
• Consideration for immunosuppressive treatment or desensiti-
sation 
• Consideration for disability grant or medical boarding for 
asthma 
Table 9: When to refer patients to a specialist/pulmonologist 
Table 8:  Causative agents and jobs/industries associated with oc-
cupational asthma 
Industry/Job type Causative Agent/s 
Animal handlers (labs./vets.) Animals, formaldehyde 
Bakeries, grain mills, farms
Flour, storage mites, 
fungi, insects, animal 
matter, amylase 
Detergent manufacture Proteolytic enzymes 
Food processing Sulphites, prawns, cof-fee beans, soya bean 
Foundries Resins, isocyanates 
Furniture, cabinet makers, sawmills Wood dust, formalde-hyde, resins 
Hospital and medical laboratories Formaldehyde, ethylene oxide, enzymes, latex 
Metal refining, plating, welding, 
turning, grinding, sharpening
Platinum, chrome, 






Photography Ethylene diamine 
Plastics or foam manufacture Isocyanates, anhy-drides, epoxy resins 
Printing Vegetable gums, acry-lates, isocyanates
Shoe industry Glues (acrylates), resins 
Soldering Colophony flux 
Spray painting or varnishing Isocyanates
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G.  ASTHMA EDUCATION AND SELF MANAGEMENT 
(ACTION) PLANS 
The effective management of asthma requires the devel-
opment of a partnership between the person with asthma 
and his or her health care professional. The aim of this 
partnership is to enable patients with asthma to gain the 
knowledge, confidence, and skills to assume a major role 
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Evidence 
Category Sources of Evidence Definition 
A Randomised controlled trials (RCTs). Rich body of data. 
Evidence is from endpoints of well designed RCTs that provide 
a consistent pattern of findings in the population for which the 
recommendation is made. Category A requires substantial 
numbers of studies involving substantial numbers of partici-
pants. 
B Randomised controlled trials (RCTs). Limited body of data. 
Evidence is from endpoints of intervention studies that include 
only a limited number of patients, posthoc or subgroup analy-
sis of RCTs, or meta-analysis of RCTs. In general, Category 
B pertains when few randomized trials exist, they are small in 
size, they were undertaken in a population that differs from the 
target population of the recommendation, or the results are 
somewhat in inconsistent. 
C Non-randomised trials. Observational studies. Evidence is from outcomes of uncontrolled or nonrandomized trials or from observational studies. 
D Panel consensus judgment. 
This category is used only in cases where the provision of 
some guidance was deemed valuable but the clinical literature 
addressing the subject was insufficient to justify placement in 
one of the other categories. The Panel Consensus is based 
on clinical experience or knowledge that does not meet the 
above-listed criteria. 
Table 10: Description of Levels of Evidence
Patients should be introduced to the National Asthma 
Education Programme (NAEP), the official asthma edu-
cation programme of the South African Thoracic Society, 
which provides free educational material and action plans 
for the self-management of asthma. Their contact details 
are: National Asthma Education Programme (South Af-
rica) - http://www.asthma.co.za, PO Box 72128 Parkview 
2122, Fax: 011 678 3069, Tel: 011 643 2755, email: 
naepr@netactive.co.za. 
Other sites offering educational material include: 
•  Allergy Society of South Africa (ALLSA) http://www. 
allergysa.org
•  The Global Initiative for Asthma http://www. ginasth-
ma.com
• National Asthma Campaign (UK) www.asthma.org.uk
•  National Heart, Lung and Blood Institute (US) www. 
nhlbi.nih.gov/ 
•  Medic Alert: (021) 425 7328
H.  LEVELS OF EVIDENCE FOR ASTHMA MANAGE-
MENT
CPD: National Guidelines
Adapted from GINA with permission
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